

Fukuda Denshi Announces the U.S. Launch of the HN-100 Neuromuscular Transmission (NMT) Monitoring Module

Fukuda Denshi launches the HN-100 NMT Module in the U.S., delivering precise EMG-based monitoring to enhance patient safety and anesthesia care.

REDMOND, WA, UNITED STATES,
October 10, 2025 /EINPresswire.com/ --

[Fukuda Denshi](#) USA, Inc. is proud to announce the U.S. launch of the HN-100 Neuromuscular Transmission

(NMT) Monitoring Module, a new solution designed to deliver accurate, quantitative neuromuscular blockade monitoring for anesthesia care in the operating room (OR) and intensive care unit (ICU).



Fukuda Denshi Logo



The launch of the HN-100 underscores Fukuda Denshi's commitment to helping hospitals improve patient outcomes while simplifying the clinician's experience."

*Justin Criddle, Vice President
of Sales*

Built on advanced surface electromyography (EMG) technology, the HN-100 enables clinicians to measure compound muscle action potential (CMAP) and quantify the depth of neuromuscular blockade – including deep levels – with exceptional precision. This innovation empowers more individualized anesthesia management and supports safer, more efficient patient care. The HN-100 leverages EMG technology from [Senzime's](#) TetraGraph® system through a collaboration with Senzime AB, further enhancing the clinical capabilities of Fukuda Denshi's monitoring solutions.

The HN-100 seamlessly integrates with Fukuda Denshi's DS-1200 patient monitoring system, allowing facilities to enhance their monitoring capabilities without changing existing workflows. It offers multiple stimulation modes, including Train-of-Four (TOF), Post-Tetanic Count (PTC), and Single Twitch (ST), and features automated stimulation settings for ease of use and optimized performance.

Advancing Patient Safety with Precision Monitoring

By enabling continuous, real-time monitoring of neuromuscular function, the HN-100 helps clinicians optimize neuromuscular blocking agent dosing, ensure adequate reversal prior to extubation, and reduce the risk of residual blockade.

Through this collaboration, Fukuda Denshi combines its expertise in patient monitoring with Senzime's proven EMG technology to deliver a next-generation solution for anesthesia care.

Its ability to assess even deep levels of paralysis provides anesthesia teams with valuable insights for safer perioperative management.



Image of HN-100 NMT Module

The module's compact design and simple integration with existing DS-1200 monitors make it a practical and efficient solution for a wide range of clinical settings, including operating rooms and intensive care units.

"The launch of the HN-100 underscores Fukuda Denshi's commitment to helping hospitals improve patient outcomes while simplifying the clinician's experience," said Justin Criddle, Vice President of Sales at Fukuda Denshi USA, Inc. "By delivering practical, integrated solutions that enhance safety, efficiency and value, we are supporting providers and achieving lasting impact for both patients and their organizations."

Availability

The HN-100 Neuromuscular Transmission (NMT) Monitoring Module is now available in the United States as part of Fukuda Denshi's DS-1200 patient monitoring system.

About Fukuda Denshi

Fukuda Denshi is a global leader in patient monitoring and diagnostic solutions, dedicated to advancing medical technology and improving patient care. With decades of experience in clinical

innovation, Fukuda Denshi delivers solutions that help healthcare professionals monitor, diagnose, and treat patients with confidence. Learn more at www.fukudaamerica.com.

****For more information:****

www.fukudaamerica.com

CustomerService@fukudaamerica.com

Customer Service

Fukuda Denshi USA, Inc.

+1 800-365-6668

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/855756854>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.